Member Info for Foxykiwi

Definately fluid leaked from the bit that sticks out between ball joints.

Unjustified fall

Buying when the market wakes up. People will just smoke more to get their fix

August news or product news before then, will provide a lift. Below analyst price range, so readying the buy signals on the Golden Cross

BERENBERG CUTS DOMINO'S PIZZA TO 'HOLD' ('BUY') - TARGET 325 (400) PENCE

of the Health bill in US on HIkma and other pharmas?

Sadly I got £95 per point on SB. I will lose £3500 when it goes down the pan but thats my problem.

05/15/2017 | 07:12am EDT BUDGET airline EASYJET looks set to deepen half-year losses this week, as it grapples with currency headwinds from the Brexit-hit pound and costs linked to launching a new European base. Analysts expect losses at the low-cost carrier to expand to around £210 million, in contrast to a £24m loss over the period last year - with the lion's share of the blow coming from sterling's weakness. The half-year results are also expected to include a £10m hit for an air operation certificate. The group is in the midst of setting up a new operating company in mainland Europe and applying for a new licence to secure flying rights for 30% of its routes after Brexit. While tomorrow's results could reveal a tough period for the firm, the airline will look to bounce back over the summer by capitalising on the trading woes of rival carriers. However, Damian Brewer, analyst at RBC Capital Markets, said the widening losses for the first half of the year will make it harder for the firm to hit full-year targets. "We see first half profit-before tax deteriorating to a £210m loss, potentially. However, the concern to us is that to make the company outlook implied £360-£370m full year profit before tax, a significant profit recovery will be required," he said, EasyJet said in January that the weak pound was expected to cost it around £105m over 2016/17

http://www.investorschronicle.co.uk/2017/05/12/shares/news-and-analysis/asthma-drug-disappointment-rocks-uk-pharma-CwdDDSP1IvhOOJeTPVMFsI/article.html IC VIEW: It seems almost inevitable that GSK will eventually lose Advair's exclusivity. It's a widely used drug and the FDA is under pressure to bring the costs down by approving a generic. The rejection may have dampened the short-term outlook, but we don't think this setback will have any long-term implications for the investment cases for Hikma or Vectura.

Any ideas as a bit confused

they have given up the licence and are just looking to set aside the costs?

.

so close to Ex Div date. You gonna wish you hadn't

Will drop below 800 I believe on FY17 being lower

.

Now its leaving the FTSE

Expecting bump up in Divi on kestrel which worth almost most the capital alone. Spoke with Company and sale of Kestrel by Rio has no bearing on the royalities they receive.

closing my t20 last week even happier opening a new one

buy on rumour sell on news...simples

Doesn't help with UBS Downgrade to 550 today